Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 39

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 39
---
 18,075                37,813  
  PRX019 (1)                                                   2,102      782               
  Other R& D (2)                                               4,720                 4,335  
  Total research and development      $                       50,811      $         64,114  

(1) R& D costs include the costs incurred from the date when PRX019 was separately tracked in preclinical development.

(2) Other R& D is comprised primarily of preclinical development and discovery programs that have not progressed to first patient dosing in a Phase 1 clinical trial, close out costs for programs that we are no longer advancing, and immaterial costs incurred on ongoing partnered programs.

General and Administrative Expenses

Our G& A expenses increased by $0.1 million for the three months ended March 31, 2025, compared to the same period in the prior.

Other Income (Expense)

                               Three Months Ended                                      Change                         
                               March 31,                                                                              
                               2025                               2024                 $                           %  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                              
  Interest income              $                       4,348      $         7,165      $           (2,817)      (39)  
  Other expense, net           (140)                              (77)                 (63)                       82  
  Total other income, net      $                       4,208      $         7,088      $           (2,880)      (41)  

Interest income decreased by $2.8 million for the three months ended March 31, 2025, compared to the same period in the prior year primarily due to lower interest income from our cash and money market accounts resulting from lower yields and lower cash balances.

Other expense, net for the three months ended March 31, 2025, w as primarily foreign exchange losses f rom transactions with vendors denominated in euros.

Provision for (benefit from) Income Taxes

                                 Three Months Ended                                          Change                       
                                 March 31,                                                                                
                                 2025                                 2024                   $                      %     
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  (Dollars in thousands)                                                                                                  
  Benefit from income taxes      $                       (1,178)      $         (2,201)      $           1,